SEARCH

SEARCH BY CITATION

References

  • 1
    Olbe L, Cederberg C, Lind T, Olausson M. Effect of omeprazole on gastric acid secretion and plasma gastrin. J Gastroenterol Hepatol 1989; 4(Suppl. 2): 19 25.
  • 2
    Creutzfeldt W & Lamberts R. Is hypergastrinaemia dangerous to man. Scand J Gastroenterol 1991; 26(Suppl. 180): 179 91.
  • 3
    Freston JW. Clinical significance of hypergastrinaemia: relevance to gastrin monitoring during omeprazole therapy. Digestion 1992; 51(Suppl. 1): 102 14.
  • 4
    Creutzfeldt W & Lamberts R. Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth. Digestion 1992; 51(Suppl. 1): 76 81.
  • 5
    Rasmussen L, Oster-Jorgensen E, Qvist N, et al. The effects of omeprazole on interdigestive motility and early postprandial levels of gastrin and secretin. Scand J Gastroenterol 1992; 27: 119 23.
  • 6
    Freston JW, Borch K, Brand SJ, et al. Effects of hypochlorhydria and hypergastrinaemia on structure and function of gastrointestinal cells. A review and analysis. Dig Dis Sci 1995; 40(Suppl. 2): S50 62.
  • 7
    Sumii M, Sumii K, Tari A, Yoshihara M, Haruma K, Kajiyama G. Regulation of antral peptides by administration of omeprazole to healthy men. Am J Gastroenterol 1994; 89: 2033 7.
  • 8
    Cunningham K, Horowitz M, Riddell P, et al. Relations among autonomic dysfunction, oesophageal motility, and gastric emptying in gastro-oesophageal reflux disease. Gut 1991; 31: 1436 40.
  • 9
    Hunt RH. Hp and pH—the relevance of gastric acid to the treatment of Helicobacter pylori infection. J Gastroenterol 1994; 29(Suppl. 7): 128 33.
  • 10
    McColl K, El Numjumi A, Dorrian C, MacDonald A, Fullarton G, Harwood J. Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy. Scand J Gastroenterol 1992; 27: 93 8.
  • 11
    McGowan C, Cover T, Blaser M. Helicobacter pylori and gastric acid biological and therapeutic implications. Gastroenterology 1996; 110: 926 38.
  • 12
    Kuipers EJ, Uyterlinde AM, Peña AS, et al. Increase of Helicobacter pylori associated corpus gastritis during acid suppressive therapy: Implications for long-term safety. Am J Gastroenterol 1995; 90: 1401 6.
  • 13
    Veenendaal RA, Pena AS, Meijer JL, et al. Long term serological surveillance after treatment of Helicobacter pylori infection. Gut 1991; 32: 1291 4.
  • 14
    Jansen JBMJ & Lamers CBHW. Effect of changes in serum calcium on secretin-stimulated serum gastrin in patients with Zollinger–Ellison syndrome. Gastroenterology 1982; 83: 173 8.
  • 15
    Westerveld BD, Pals G, Lamers Cbhw, et al. Clinical significance of pepsinogen isoenzymogens, serum pepsinogen A and C levels and serum gastrin levels. Cancer 1987; 59: 952 8.
  • 16
    Biemond I, Jansen JBMJ, Crobach LFSJ, Kreuning J, Lamers CBHW. Radioimmunoassay of human pepsinogen A and pepsinogen C. J Clin Chem Clin Biochem 1989; 27: 19 25.
  • 17
    Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The up-dated Sydney system. Am J Surg Pathol 1996; 20: 1161 81.
  • 18
    Oedam L, Petersen HD, Andersen IB, Hansen BF, Rehfeld JF. Gastrin and somatostatin in Helicobacter pylori infected antral mucosa. Gut 1994; 35: 615 18.
  • 19
    Götz JM, Veenendaal RA, Biemond I, Muller ESM, Veselic M, Lamers CBHW. Serum somatostatin in Helicobacter pylori associated gastritis . Scand J Gastroenterol 1995; 30: 1064 8.
  • 20
    Jansen EV, Horbach JMLM, Klamer M, et al. Plasma pancreatic polypeptide responses to insulin hypoglycaemia after Nissen fundoplication. Scand J Gastroenterol 1989; 24(Suppl. 171): 9 12.
  • 21
    Jansen E. Clinical value of vagus nerve integrity testing by pancreatic polypeptide. PhD thesis, Leiden University, the Netherlands, 1990.
  • 22
    Lamers CBHW, Diemel CM, Leer van E, Leusen van R, Peetom JJ. Mechanism of elevated serum polypeptide concentrations in chronic renal failure. J Clin Endocrinol Metab 1982; 55: 922 6.
  • 23
    Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35(Suppl. 1): 42 55.
  • 24
    Driman DK, Wright C, Tougas G, Riddell RH. Omeprazole produces parietal cell hypertropy and hyperplasia in humans. Dig Dis Sci 1996; 41: 2039 47.
  • 25
    Solcia E, Rindi G, Havu N, Elm G. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole. Scand J Gastroenterol 1989; 24(Suppl. 166): 129 37.
  • 26
    Creutzfeldt W, Lamberts R, Stöckmann F, Brunner G. Quantitative studies of gastric endocrine cells in patients receiving long-term treatment with omeprazole. Scand J Gastroenterol 1989; 24(Suppl. 166): 122 8.
  • 27
    Wagner S, Haruma K, Gladziwa U, et al. Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: Significance of inflammation and effect of bacterial eradication. Am J Gastroenterol 1994; 89: 1211 18.
  • 28
    Schlemper RJ, Van Der Werf SDJ, Vandenbroucke JP, Biemond I, Lamers CBHW. Seroepidemiology of gastritis in Japanese and Dutch working populations: evidence for the development of atrophic gastritis that is not related to Helicobacter pylori. Gut 1995; 37: 199 204.
  • 29
    Graham DY, Opekun A, Lwe GM, Evans DJ, Klein PD, Evans DG. Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter (Campylobacter) pylori infection. Am J Gastroenterol 1990; 85: 394 8.
  • 30
    Smith JT, Pounder RE, Nwokolo CU, Lanzon-Miller S, Evans DG. Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut 1990; 31: 522 5.
  • 31
    Sumii M, Suimii K, Tari A, et al. Effect of omeprazole on regulation of antral somatostatin in human beings. Biomed Res 1995; 16: 339 41.